文献速递核素与放射性配体治疗

序贯双肽受体放射性核素治疗大体积神经内分泌肿瘤:90Y-DOTATATE治疗后轫致辐射与PET/CT显像

Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
PubMed 文献 · Clin Nucl Med · 2020-01-01

文中指出177Lu因β能量较低(Eβmax 0.497 MeV)和射程较短在大体积肿瘤中疗效降低,而纯β发射体90Y因β射程较长对大体积肿瘤更有效,但需平衡90Y-DOTATATE相关肾毒性风险。

要点

  • 177Lu因β能量较低(Eβmax 0.497 MeV)和射程较短,在大体积神经内分泌肿瘤中疗效降低。
  • 纯β发射体90Y因β射程较长,对大体积肿瘤更有效,但90Y-DOTATATE相关肾毒性风险更高。
  • 序贯双肽受体放射性核素治疗可能使大体积异质性神经内分泌肿瘤获得更好疗效且不良反应最小。

核心结论

  • 177Lu在大体积神经内分泌肿瘤中疗效降低,90Y因β射程较长对大体积肿瘤更有效,但需平衡90Y-DOTATATE相关肾毒性风险。
  • 序贯双肽受体放射性核素治疗可能使大体积异质性神经内分泌肿瘤获得更好疗效且不良反应最小。

研究设计与样本

  • 本文为一名56岁男性直肠神经内分泌肿瘤伴大体积肝转移患者的病例报告。
  • 患者接受90Y-DOTATATE与177Lu-DOTATATE序贯双肽受体放射性核素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficacy of Lu-DOTATATE in large neuroendocrine tumors (NETs) is reduced because of the lower energy (Eβmax 0.497 MeV) and shorter range of Lu. The pure β-emitter Y with its longer β range is more effective in larger tumors. This should be balanced with the greater risk of Y-DOTATATE-related nephrotoxicity. Sequential duo-peptide receptor radionuclide therapy may result in a better response with minimal adverse effects in large-volume heterogeneous NETs. A 56-year-old man with large rectal NET liver metastases, treated with Y-DOTATATE and Lu-DOTATATE and sequential duo-peptide receptor radionuclide therapy, presented with post-Y-DOTATATE bremsstrahlung and PET/CT in comparison with Ga-DOTATATE PET/CT and Lu-DOTATATE scans.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Parghane RV, Mitra A, Upadhye T, et al. Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment. Clin Nucl Med. 2020. PMID: 32657872. doi:10.1097/RLU.0000000000003182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。